Compare iShares MSCI Germany (DAX) (EWG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI Germany (DAX) trades at $41.16, while IDEXX Laboratories, Inc. trades at $574.15 (market cap $43.94B). The key difference: iShares MSCI Germany (DAX) is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| EWG | IDXX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $766.68 |
52-Week Low | $38.08 | $514.61 |
Market Cap | — | $43.94B |
Enterprise Value | — | $44.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $41.19, down 0.48% on the day with a neutral technical signal. The stock shows mixed technical indicators with bearish moving averages but oversold RSI conditions. Recent German economic developments, including a €13.3 billion energy relief package and healthcare reforms, create a complex backdrop for this US-listed German-focused ETF.
The outlook remains balanced with European monetary policy uncertainty and energy market volatility presenting both opportunities and risks. German fiscal support measures could provide stability, while ECB rate decisions and Middle East tensions may drive near-term volatility in European markets.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
